Medical Condition News

RSS

People with chronic insomnia may be able to get relief from half of standard sleeping pills

The roughly nine million Americans who rely on prescription sleeping pills to treat chronic insomnia may be able to get relief from as little as half of the drugs, and may even be helped by taking placebos in the treatment plan, according to new research published today in the journal Sleep Medicine by researchers from the Perelman School of Medicine at the University of Pennsylvania.

4 Aug 2015

Research finding could help reveal how the human brain learns complex motor skills

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. To learn and improve, the songbird brain needs to shake up its tried-and-true patterns with a healthy dose of creative experimentation. Until now, no one has found a specific mechanism by which this could occur.

4 Aug 2015

BrightFocus announces recipients of 2015 research program grants

BrightFocus Foundation, which funds research worldwide on Alzheimer's disease, glaucoma, and macular degeneration, today announced that its 2015 research program grants have been awarded to 58 scientists in 20 states and 7 foreign countries. Part of an $11 million research investment, the grants reflect the largest annual research funding in the foundation's history.

4 Aug 2015

Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

Soldiers who served in the glaring desert sunlight of Iraq and Afghanistan returned home with an increased risk of skin cancer, due not only to the desert climate, but also a lack of sun protection, Vanderbilt dermatologist Jennifer Powers, M.D., reports in a study published recently in the Journal of Investigative Dermatology.

4 Aug 2015

Weight cycling not associated with overall risk of cancer

The first comprehensive study of its kind finds weight cycling, repeated cycles of intentional weight loss followed by regain, was not associated with overall risk of cancer in men or women. The study by American Cancer Society investigators is the largest to date to investigate weight cycling with cancer risk.

4 Aug 2015

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

Skin cancer is the most common of all cancers, and melanoma, which accounts for 2% of skin cancer cases, is responsible for nearly all skin cancer deaths. Melanoma rates in the US have been rising rapidly over the last 30 years, and although scientists have managed to identify key risk factors, melanoma's modus operandi has eluded the world of medical research.

4 Aug 2015

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Researchers at the Johns Hopkins University School of Medicine, Johns Hopkins University Department of Chemical and Biomolecular Engineering, and Federal University of Rio de Janeiro in Brazil have designed a DNA-loaded nanoparticle that can pass through the mucus barrier covering conducting airways of lung tissue — proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases.

4 Aug 2015

Scientists successfully test new tumor diagnosis method

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf, in cooperation with colleagues at the University of Zurich and the Ruhr-Universität Bochum, have for the first time successfully tested a new tumor diagnosis method under near-real conditions. The new method first sends out an antibody as a "spy" to detect the diseased cells and then binds to them.

4 Aug 2015

Engineered protein shown effective in patients with severe von Willebrand disease

The first protein engineered to help control bleeding episodes in patients with severe von Willebrand disease (vW disease) has been shown to be safe and effective, according to results of a Phase III trial.

4 Aug 2015

New big data collaboration aims to improve care management for diabetes, mental health

Duke-NUS Graduate Medical School Singapore and Holmusk, a global tele-health platform, have recently announced a collaboration to further the potential of big data in healthcare. Big data refers to very large, unstructured and diverse datasets that cannot be managed using conventional methods. In healthcare, big data and analytics allow us to discover patterns that would not be found otherwise, and make predictions about disease. This has the potential to improve care and lower costs.

4 Aug 2015

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).

3 Aug 2015

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

3 Aug 2015

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced a collaboration with Galectin Therapeutics to use the BreathID test to monitor patients in a Phase II study evaluating GR-MD-02.

3 Aug 2015

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T.

3 Aug 2015

RNA-binding protein ROQUIN regulates response to DNA damage

Messenger (mRNA) molecules are a key component of protein biosynthesis. They are first transcribed as a "working copy" of the DNA and then translated into protein molecules.

3 Aug 2015

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China.

3 Aug 2015

Medical Condition News

People with chronic insomnia may be able to get relief from half of standard sleeping pills

Research finding could help reveal how the human brain learns complex motor skills

BrightFocus announces recipients of 2015 research program grants

Soldiers returning from combat missions in Iraq and Afghanistan at increased risk of skin cancer

Weight cycling not associated with overall risk of cancer

New Tel Aviv University study sheds light on precise trigger of deadly melanoma

First biodegradable gene delivery system efficiently penetrates human airway mucus barrier of lung tissue

Scientists successfully test new tumor diagnosis method

Engineered protein shown effective in patients with severe von Willebrand disease

New big data collaboration aims to improve care management for diabetes, mental health

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

Shionogi’s naldemedine meets primary, secondary endpoints for treatment of opioid-induced constipation

Exalenz Bioscience, Galectin Therapeutics to use BreathID test to assess GR-MD-O2 efficacy in NASH Cirrhosis patients

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

RNA-binding protein ROQUIN regulates response to DNA damage

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Isis Pharmaceuticals, AstraZeneca to develop antisense therapies for cardiovascular, metabolic, renal diseases

Anti-dementia drugs could result in harmful weight loss, say researchers

New MS therapies associated with risks and side effects, require active management strategy

BUSM researchers find new way to detect and treat basal-like breast cancer

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Automation in cell-based workflows

Latest News